hCD3EDG/hEpCAM

Nomenclature

C57BL/6Smoc-Cd3etm1(hCD3E)Cd3dtm1(hCD3D)Cd3gtm1(hCD3G)Epcamtm1(hEPCAM)Smoc

Cat. NO.

NM-HU-220123

Strain State

Repository Live

Export PDF

Model Description

hCD3EDG(NM-HU-220120) mice were crossed with hEpCAM(NM-HU-210032) mice to generate hCD3EDG/hEpCAM mice.

Validation Data

Table.1 Blood routine examination in male hCD3EDG/hEpCAM mice.

image.png

Table.2 Blood routine examination in female hCD3EDG/hEpCAM mice.

image.png


image.png

Fig.1 Detection of lymphcytes population in the (A) peripheral blood and (B) spleen of 8-week-old male and female homozygous hCD3EDG/hEpCAM dKI mice by FACS (n=3). 

image.png

Fig.2 Pathological analysis of 8-week-old female hCD3EDG/hEpCAM dKI mice by H＆E staining. 

There were no obvious pathological changes in these tissues.

image.png

Fig.3 Pathological analysis of 8-week-old male hCD3EDG/hEpCAM dKI mice by H＆E staining. 

There were no obvious pathological changes in these tissues.

image.png

Fig.4 Detection of mouse EpCAM expression in 8-week-old wild-type mice (WT) by IHC with an anti-mouse EpCAM antibody (Abcam, ab221552). 

The arrows indicate the positive mouse EpCAM staining (brown) in each tissue. (40x Magnification) 

image.png

Fig.5 Detection of human EpCAM expression in 8-week-old wild-type mice (WT) and homozygous hCD3EDG/hEpCAM knockin mice by IHC with an anti-human EpCAM antibody (Abcam, ab223582). 

The arrows indicate the positive EpCAM staining (brown) in each tissue. The results show that human EpCAM is highly expressed in the intestine and kidney of hCD3EDG/hEpCAM knockin mice. (40x Magnification)  

You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more